SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
We are pleased to enclose herewith our Press Release relating to announcement of financial results for the third quarter and nine month ending December 31, 2019, which we shall be releasing after sending this letter to you. This is for your information and record. Thanking you, SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Shareholding for the Period Ended December 31, 2019
Sun Pharmaceutical Industries Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2019. For more details, kindly Click here Sun Pharmaceutical Industries Ltd - 524715 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on January 17, 2020 for Aditya Medisales Ltd SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Board Meeting Intimation for Notice Of Board Meeting For Consideration And Approval Of Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter And Nine Months Ended December 31, 2019
SUN PHARMACEUTICAL INDUSTRIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/02/2020 ,inter alia, to consider and approve This is to inform you that the meeting of the Board of Directors of the Company will be held on Thursday, February 06, 2020, to inter alia consider and approve Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and nine months ended December 31, 2019. This is for your information and record. Sun Pharmaceutical Industries Ltd - 524715 - Statement Of Investor Complaints For The Quarter Ended December 2019
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0110 Name of the Signatory :- Ashok BhutaDesignation :- Authorised Signatory Sun Pharma, US-based Rockwell Medical enter into licensing pact for Triferic
Sun Pharmaceutical Industries on Wednesday said it has entered into a licensing agreement with US-based Rockwell Medical to commercialise Triferic - SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Please find enclosed intimation pursuant to Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Sun Pharmaceutical Industries Ltd - 524715 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Please find enclosed herewith our Press Release relating to License Agreement with Rockwell Medical for Triferic in India, which we shall be releasing after sending this letter to you. This is for your information and record. Thanking you, Sun Pharmaceutical Industries Ltd - 524715 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Please find enclosed certificate under Regulation 74(5) of Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018 for the quarter ended 31st December, 2019. Sun Pharmaceutical Industries Ltd - 524715 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Please find enclosed certificate under Regulation 74(5) of Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018 for the quarter ended 31st December, 2019.